Skip to main content

Experimental Hematology & Oncology

Ausgabe 1/2015

Inhalt (34 Artikel)

Open Access Review

New frontiers for platelet CD154

Antoine Dewitte, Annabelle Tanga, Julien Villeneuve, Sébastien Lepreux, Alexandre Ouattara, Alexis Desmoulière, Christian Combe, Jean Ripoche

Open Access Review

Selective inhibitors of nuclear export (SINE) in hematological malignancies

Arundhati Das, Guoqing Wei, Kaushal Parikh, Delong Liu

Open Access Case report

Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia

Heidys Garrote, Adolfo de la Fuente, Raquel Oña, Inmaculada Rodríguez, Juan E Echevarría, Juan M Sepúlveda, Juan F García

Open Access Research

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma

Seong-Su Han, Van S Tompkins, Dong-Ju Son, Sangwoo Han, Hwakyung Yun, Natalie L Kamberos, Casey L Dehoedt, Chunyan Gu, Carol Holman, Guido Tricot, Fenghuang Zhan, Siegfried Janz

Open Access Research

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis

Georg Hess, Bertrand Coiffier, Michael Crump, Christian Gisselbrecht, Fritz Offner, Jorge Romaguera, Lisa Kang, Pádraig J Moran

Open Access Research

Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1

Shiho Fujiwara, Naoko Wada, Yawara Kawano, Yutaka Okuno, Yoshitaka Kikukawa, Shinya Endo, Nao Nishimura, Nina Ueno, Hiroaki Mitsuya, Hiroyuki Hata

Open Access Research

Immunosuppressive mechanisms of human bone marrow derived mesenchymal stromal cells in BALB/c host graft versus host disease murine models

Joseph Delano Robles, Yin Ping Liu, Jiamin Cao, Zheng Xiang, Yin Cai, Michael Manio, Eva HC Tang, Godfrey Chi-Fung Chan

Open Access Research

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia

Yajuan Cui, Hongyan Tong, Xin Du, Bing Li, Robert Peter Gale, Tiejun Qin, Jinqin Liu, Zefeng Xu, Yue Zhang, Gang Huang, Jie Jin, Liwei Fang, Hongli Zhang, Lijuan Pan, Naibo Hu, Shiqiang Qu, Zhijian Xiao

Open Access Research

Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies

Marita C. Lynagh, Tara Clinton-McHarg, Alix Hall, Rob Sanson-Fisher, William Stevenson, Campbell Tiley, Alessandra Bisquera

Open Access Letter to the Editor

Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response

Arpana Kamath, Ann M Joseph, Kumud Gupta, Digamber Behera, Anand Jaiswal, Ravindra Dewan, Maitreyi S Rajala

Open Access Research

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma

Francesco Pisani, Rosa Sciuto, Maria Laura Dessanti, Diana Giannarelli, Ramy Kayal, Sandra Rea, Francesco Marchesi, Mirella Marino

Open Access Short report

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma

Magalie P. Tardy, Lauris Gastaud, Mario Ojeda-Uribe, Annick Boscagli, Salvatore Caruso, Richard Skaf, Jean Gutnecht, Antoine Thyss, Frédéric Peyrade

Open Access Research

Melanoma tumor growth is accelerated in a mouse model of sickle cell disease

Jintao Wang, Jennifer Tran, Hui Wang, Wei Luo, Chiao Guo, David Harro, Andrew D. Campbell, Daniel T. Eitzman

Open Access Research

Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma

Ruth-Miriam Koerber, Stefanie Andrea Erika Held, Annkristin Heine, Philipp Kotthoff, Solveig Nora Daecke, Anita Bringmann, Peter Brossart

Open Access Research

Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study

Christina Dicke, Ali Amirkhosravi, Brigitte Spath, Miguel Jiménez-Alcázar, Tobias Fuchs, Monica Davila, John L Francis, Carsten Bokemeyer, Florian Langer

Open Access Research

Effect of IKZF1 deletions on signal transduction pathways in Philadelphia chromosome negative pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL)

Naomi E van der Sligte, Frank J G Scherpen, Arja ter Elst, Victor Guryev, Frank N van Leeuwen, Eveline S J M de Bont

Open Access Case report

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma

Enrico Derenzini, Ilaria Iacobucci, Claudio Agostinelli, Enrica Imbrogno, Clelia Tiziana Storlazzi, Alberto L`Abbate, Beatrice Casadei, Anna Ferrari, Andrea Ghelli Luserna Di Rora`, Giovanni Martinelli, Stefano Pileri, Pier Luigi Zinzani

Open Access Review

Novel antidotes for target specific oral anticoagulants

Arundhati Das, Delong Liu

Open Access Research

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Mary Frances McMullin, Claire N. Harrison, Dietger Niederwieser, Hilde Demuynck, Nadja Jäkel, Prashanth Gopalakrishna, Mari McQuitty, Viktoriya Stalbovskaya, Christian Recher, Koen Theunissen, Heinz Gisslinger, Jean-Jacques Kiladjian, Haifa-Kathrin Al-Ali

Open Access Short report

CD57+ T-cells are a subpopulation of T-follicular helper cells in nodular lymphocyte predominant Hodgkin lymphoma

Ahmad Sattarzadeh, Arjan Diepstra, Bea Rutgers, Anke van den Berg, Lydia Visser

Open Access Review

GATA family transcriptional factors: emerging suspects in hematologic disorders

Juehua Gao, Yi-Hua Chen, LoAnn C. Peterson

Open Access Case report

Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing

Diana Mandelker, Paola Dal Cin, Heather A. Jacene, Philippe Armand, Richard M. Stone, Neal I. Lindeman

Open Access Research

Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US

Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, Erika Ohashi, Valerie Koo, Eric Q. Wu

Open Access Research

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Ying Wang, Zenghui Xu, Fuping Zhou, Yan Sun, Jingbo Chen, Linfang Li, Huajun Jin, Qijun Qian

Open Access Review

Breast cancer brain metastases: the last frontier

José Pablo Leone, Bernardo Amadeo Leone

Open Access Case report

Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: clonal evolution unchecked

Polly Niravath, Tanya Eble, Alejandro Contreras, Marilyn Li, Luis M Franco, Mothaffar Rimawi

Open Access Case report

Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report

Silvia Tedesco, Laura Postacchini, Lucia Manfredi, Gaia Goteri, Michele M Luchetti, Antonella Festa, Armando Gabrielli, Giovanni Pomponio

Open Access Review

Distinct genetic alterations in small cell carcinoma from different anatomic sites

Xiaoyong Zheng, Delong Liu, John T Fallon, Minghao Zhong

Open Access Research

The effect of caffeine on cisplatin-induced apoptosis of lung cancer cells

Gan Wang, Vanitha Bhoopalan, David Wang, Le Wang, Xiaoxin Xu

Open Access Rapid communication

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

Jesper Kofoed Damm, Sandra Gordon, Mats Ehinger, Mats Jerkeman, Urban Gullberg, Anne Hultquist, Kristina Drott

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.